Loading asset research
Taysha Gene Therapies Inc. Common Stock
TSHANasdaq · USD · StocksQuote as of · Exchange session not verified$5.01
-2.81%
Today
TSHA
Loading 1D prices…
Market cap
$1.6B
Volume
1.8M
52w high
$7.3052w low
$2.71Company profile
Taysha Gene Therapies Inc. Common Stock
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Dallas, TX, United States
Employees
99
Fiscal year end
1231
CIK
1806310
Session & valuation
Open$5.26
Previous close$5.16
Day high$5.28
Day low$4.98
30-day avg. volume2.4M
Outstanding shares325.8M
Diluted EPS-$0.34
Latest annual period
P/E (trailing)-14.75
P/E (forward)-10.85
Price / book6.80
Beta1.17
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| INBXInhibrx Biosciences Inc. Common Stock | $1.6B | $1.3M | -10773.46% | -$9.04 | -2.23% | Buy |
| IMCRImmunocore Holdings plc American Depositary Shares | $1.7B | $400M | -8.88% | -$0.71 | -3.04% | Buy |
| RXRXRecursion Pharmaceuticals Inc. Class A Common Stock | $1.7B | $74.7M | -863.35% | -$1.44 | +1.11% | Hold |
| NVAXNovavax Inc. Common Stock | $1.6B | $1.1B | +39.19% | $2.58 | +1.34% | Hold |
| VIRVir Biotechnology Inc. Common Stock | $1.8B | $68.6M | -638.87% | -$3.16 | +0.33% | Buy |